Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

Company Performance - Moderna's stock closed at $33.64, down 1.87%, underperforming the S&P 500's daily loss of 0.33% [1] - Over the previous month, Moderna's shares gained 25.34%, outperforming the Medical sector's loss of 0.32% and the S&P 500's gain of 4.07% [1] Upcoming Earnings - The upcoming earnings release is anticipated, with an expected EPS of -$2.97, reflecting a 10.81% increase from the same quarter last year [2] - Revenue is forecasted at $130.15 million, indicating a 46% decline compared to the same quarter last year [2] Full-Year Estimates - Zacks Consensus Estimates predict full-year earnings of -$9.81 per share and revenue of $2.08 billion, representing year-over-year changes of -10.6% and -35.83%, respectively [3] - Recent changes in analyst estimates are crucial for investors, as positive revisions indicate optimism regarding business and profitability [3] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown a strong track record, with 1 stocks delivering an average annual return of +25% since 1988 [5] - Currently, Moderna holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate moving 0.26% lower over the last 30 days [5] Industry Overview - The Medical - Biomedical and Genetics industry ranks in the top 31% of all industries, with a current Zacks Industry Rank of 76 [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]